Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate
- Novavax’ proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at
Jenner Instituteat Oxford University
- Phase 2b clinical efficacy study of experimental malaria vaccine with Matrix‑M nearing completion in
Under the terms of the agreement, SII is granted rights to use Matrix-M in the vaccine in regions where the disease is endemic and will pay
In addition, as part of the arrangement,
“Novavax’ next-generation adjuvant, Matrix-M, is an impressive and critical component in this much-needed malaria vaccine,” said
“As the world’s largest vaccine producer in terms of doses delivered,
Malaria is a serious and sometimes fatal disease caused by at least four different parasites that are found on certain types of mosquitos. Plasmodium falciparum, the most severe of these parasites, causes the type of malaria that is most likely to result in severe infections and, if not promptly treated, can lead to death. There are approximately 2,000 annual cases of malaria diagnosed in the
Matrix-M™ is Novavax’ next-generation saponin-based adjuvant, powered by a novel formulation that provides a potent and well-tolerated adjuvant effect. Saponins are steroid or triterpenoid glycosides, which occur in many plant species. In Matrix-M, purified saponin fractions are mixed with synthetic cholesterol and a phospholipid to form stable particles than can be readily formulated with a variety of vaccine antigens. Saponin-based adjuvants act in part by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in the local lymph nodes. Matrix-M has the ability to stimulate cell-mediated immunity as well as to enhance antibody production; and importantly, when facing rapidly emerging diseases such as those caused by coronaviruses, Ebola virus or pandemic influenza, they can allow immune responses to be achieved with much lower doses of antigen, known as “dose-sparing.” Matrix-M also increases the opportunity for longer-lasting immunity, which may reduce the number of vaccinations needed to gain optimal protection.
Novavax’ past experience with saponin-based adjuvants in both animals and humans indicates that, like all adjuvants, they increase the local reaction at the injection site. However, those local reactions are transient and there is no evidence of longer-term adverse effects. Matrix-M has been evaluated in several
1 WHO 2019 World Malaria Report https://www.who.int/publications-detail/world-malaria-report-2019
Serum is ranked as
The philanthropic philosophy of Serum continues with its work on newer vaccines and biologicals.
Learn more about
Statements herein relating to the future of
Brandzone/Speak Life Science
Source: Novavax, Inc.